Arcturus Therapeutics Holdings (ARCT) Operating Income (2018 - 2026)

Arcturus Therapeutics Holdings has reported Operating Income for 9 years, with the latest figure at -$28.9 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Income fell 71.94% year-over-year to -$28.9 million; the trailing twelve-month figure through Mar 2026 stood at -$88.4 million (down 7.65% YoY), and the FY2025 full-year result was -$76.3 million, up 20.29% from the prior year.
• Operating Income for Q1 2026 stood at -$28.9 million, up from -$31.3 million in the prior quarter.
• The five-year high for Operating Income was $121.5 million in Q4 2022, with the low at -$55.4 million in Q2 2023.
• Historically, Operating Income has averaged -$15.7 million across 5 years, with a median of -$21.1 million in 2024.
• Annual changes were most pronounced in 2022 — Operating Income jumped 422.62% — and 2024, when it tumbled 306.11%.
• Arcturus Therapeutics Holdings' Operating Income stood at $121.5 million in 2022, then tumbled by 115.04% to -$18.3 million in 2023, then tumbled by 82.76% to -$33.4 million in 2024, then grew by 6.25% to -$31.3 million in 2025, then gained by 7.59% to -$28.9 million in 2026.
• The last three Operating Income figures came in at -$28.9 million (Q1 2026), -$31.3 million (Q4 2025), and -$16.5 million (Q3 2025), per Business Quant data.